Galderma Improves Clobex Nozzle Design

An improved nozzle design for Galderma Laboratories L.P.’s Clobex Spray helps psoriasis sufferers apply the medication more easily and precisely. The new packaging for Clobex Spray, which will be on pharmacy shelves nationwide later this month, features a more targeted nozzle delivery system to help psoriasis patients apply the product more easily and precisely to affected areas of the body and scalp.

“Successful treatment of plaque psoriasis with topical steroids hinges upon a patient’s ability to regularly and accurately apply the medication to localized lesions,” says Dr. Fran Cook-Bolden, director of the Skin Specialty Group and assistant clinical professor of dermatology at Columbia University in New York. “Clobex Spray is already a trusted, easy-to-use treatment option for psoriasis. I think the new nozzle will enhance the patient’s experience with this medication by making the application process simpler and more targeted, and will give patients the Clobex efficacy they’ve come to trust while limiting potential medication overuse.”

Clobex Spray is a super-potent topical steroid indicated to treat moderate to severe plaque psoriasis in patients 18 years and older. Psoriasis is a disorder in which skin grows and replaces itself too rapidly, causing a buildup of red, thickened areas with silvery scales. These scales flake off easily and often, causing the red areas to grow larger still — and the cycle continues. The National Institutes of Health estimates that as many as 7.5 million people in the U.S. have psoriasis. The condition usually develops in adults on the scalp, elbows, knees and lower back and can be painful, itchy and sometimes disfiguring in its moderate to severe forms.

Topical steroids are often prescribed by dermatologists to help people with psoriasis get their condition under control. Clobex Spray is a powerful topical steroid that comes in easy-to-use 2 oz. and 4.25 oz. bottles with a non-aerosol, measured-dose spray, and provides clinically proven relief of common symptoms associated with psoriasis.

The efficacy of Clobex Spray was established in two independent clinical trials with 240 patients. On average, eight out of 10 patients with moderate to severe plaque psoriasis became clear or almost clear after four weeks of treatment, and the efficacy of Clobex Spray to treat moderate to severe plaque psoriasis has been confirmed in various clinical studies since its approval. The updated nozzle delivery system allows patients to target the application of Clobex Spray to the affected areas of their body and scalp.